The Experts below are selected from a list of 156 Experts worldwide ranked by ideXlab platform
Hitoshi Okamura - One of the best experts on this subject based on the ideXlab platform.
-
Successful treatment with Bromocriptine of hypertension associated with polycystic ovarian disease.
Acta Obstetricia et Gynecologica Scandinavica, 2011Co-Authors: Kohei Matsuura, Aiko A, Kazuo Matsui, Toshihiro Yoshimura, Hitoshi OkamuraAbstract:The use of Bromocriptine, 5 mg per day, markedly improved the severe hypertension (up to 180/120 mmHg) of a patient suffering from polycystic ovarian disease (PCOD). The response was rapid, with decreasing concentrations of serum testosterone and 11-deoxycorticosterone (DOC). Bromocriptine induced further renewal of the ovulatory cycle. Bromocriptine may thus be of considerable value in the treatment hypertensive patients with PCOD.
Anthony H Cincotta - One of the best experts on this subject based on the ideXlab platform.
-
Bromocriptine unique formulation of a dopamine agonist for the treatment of type 2 diabetes
Expert Opinion on Pharmacotherapy, 2010Co-Authors: Richard E Scranton, Anthony H CincottaAbstract:Importance to the field: There is a large unmet need for new therapies to treat type 2 diabetes (T2DM) which reduce fasting and postprandial glucose without increasing insulin levels and which are not associated with weight gain or hypoglycemia. The quick-release formulation of Bromocriptine (Bromocriptine-QR; Cycloset™) represents such a therapy.Areas covered in the review: Bromocriptine-QR's proposed mechanism of action, unique formulation and clinical efficacy and safety will be discussed. A Medline search was conducted using the terms: Bromocriptine quick-release, circadian rhythms, treatment type 2 diabetes, insulin resistance, beta-cell dysfunction (years 1985 – 2009).What the reader will gain: The reader will gain an understanding of the importance of the brain as a target for the treatment of type 2 diabetes. In addition the safety, efficacy and indication for use of a first-in-class dopamine agonist as a treatment option for type 2 diabetes are discussed.Take home message: Bromocriptine-QR is ind...
-
Bromocriptine a novel approach to the treatment of type 2 diabetes
Diabetes Care, 2000Co-Authors: Hanno Pijl, Shinichiro Ohashi, Masafumi Matsuda, Yoshinori Miyazaki, Archana Mahankali, Vineeta Kumar, Ruben Pipek, Patricia Iozzo, Jack L Lancaster, Anthony H CincottaAbstract:OBJECTIVE: In vertebrates, body fat stores and insulin action are controlled by the temporal interaction of circadian neuroendocrine oscillations. Bromocriptine modulates neurotransmitter action in the brain and has been shown to improve glucose tolerance and insulin resistance in animal models of obesity and diabetes. We studied the effect of a quick-release Bromocriptine formulation on glucose homeostasis and insulin sensitivity in obese type 2 diabetic subjects. RESEARCH DESIGN AND METHODS: There were 22 obese subjects with type 2 diabetes randomized to receive a quick-release formulation of Bromocriptine (n = 15) or placebo (n = 7) in a 16-week double-blind study. Subjects were prescribed a weight-maintaining diet to exclude any effect of changes in body weight on the primary outcome measurements. Fasting plasma glucose concentration and HbA(1c) were measured at 2- to 4-week intervals during treatment. Body composition (underwater weighing), body fat distribution (magnetic resonance imaging), oral glucose tolerance (oral glucose tolerance test [OGTT]), insulin-mediated glucose disposal, and endogenous glucose production (2-step euglycemic insulin clamp, 40 and 160 mU x min(-1) x m(-2)) were measured before and after treatment. RESULTS: No changes in body weight or body composition occurred during the study in either placebo- or Bromocriptine-treated subjects. Bromocriptine significantly reduced HbA(1c) (from 8.7 to 8.1%, P = 0.009) and fasting plasma glucose (from 190 to 172 mg/dl, P = 0.02) levels, whereas these variables increased during placebo treatment (from 8.5 to 9.1%, NS, and from 187 to 223 mg/dl, P = 0.02, respectively). The differences in HbA(1c) (delta = 1.2%, P = 0.01) and fasting glucose (delta = 54 mg/dl, P < 0.001) levels between the Bromocriptine and placebo group at 16 weeks were highly significant. The mean plasma glucose concentration during OGTT was significantly reduced by Bromocriptine (from 294 to 272 mg/dl, P = 0.005), whereas it increased in the placebo group. No change in glucose disposal occurred during the first step of the insulin clamp in either the Bromocriptine- or placebo-treated group. During the second insulin clamp step, Bromocriptine improved total glucose disposal from 6.8 to 8.4 mg x min(-1) kg(-1) fat-free mass (FFM) (P = 0.01) and nonoxidative glucose disposal from 3.3 to 4.3 mg min(-1) x kg(-1) FFM (P < 0.05), whereas both of these variables deteriorated significantly (P < or = 0.02) in the placebo group. CONCLUSIONS: Bromocriptine improves glycemic control and glucose tolerance in obese type 2 diabetic patients. Both reductions in fasting and postprandial plasma glucose levels appear to contribute to the improvement in glucose tolerance. The Bromocriptine-induced improvement in glycemic control is associated with enhanced maximally stimulated insulin-mediated glucose disposal.
Kohei Matsuura - One of the best experts on this subject based on the ideXlab platform.
-
Successful treatment with Bromocriptine of hypertension associated with polycystic ovarian disease.
Acta Obstetricia et Gynecologica Scandinavica, 2011Co-Authors: Kohei Matsuura, Aiko A, Kazuo Matsui, Toshihiro Yoshimura, Hitoshi OkamuraAbstract:The use of Bromocriptine, 5 mg per day, markedly improved the severe hypertension (up to 180/120 mmHg) of a patient suffering from polycystic ovarian disease (PCOD). The response was rapid, with decreasing concentrations of serum testosterone and 11-deoxycorticosterone (DOC). Bromocriptine induced further renewal of the ovulatory cycle. Bromocriptine may thus be of considerable value in the treatment hypertensive patients with PCOD.
Serdar Durdagi - One of the best experts on this subject based on the ideXlab platform.
-
structural investigation of the dopamine 2 receptor agonist Bromocriptine binding to dimeric d2highr and d2lowr states
Journal of Chemical Information and Modeling, 2018Co-Authors: Ramin Ekhteiari Salmas, Philip Seeman, Matthias Stein, Serdar DurdagiAbstract:The active (D2HighR) and inactive (D2LowR) states of dimeric dopamine D2 receptor (D2R) models were investigated to clarify the binding mechanisms of the dopamine agonist Bromocriptine, using Molecular Dynamics (MD) simulation. The aim of this comprehensive study was to investigate the critical effects of Bromocriptine binding on each distinct receptor conformation. The different binding modes of the Bromocriptine ligand in the active and inactive states have a significant effect on the conformational changes of the receptor. Based on the MM/GBSA approach, the calculated binding enthalpies of Bromocriptine demonstrated selectivity toward the D2HighR active state. There is good agreement between the calculated and experimentally measured D2HighR selectivity. In the ligand-binding site, the key amino acids identified for D2HighR were Asp114(3.32) and Glu95(2.65), and for D2LowR, it was Ser193(5.42). Moreover, analysis of replicate MD trajectories demonstrated that the Bromocriptine structure was more rigid ...
Richard E Scranton - One of the best experts on this subject based on the ideXlab platform.
-
Bromocriptine unique formulation of a dopamine agonist for the treatment of type 2 diabetes
Expert Opinion on Pharmacotherapy, 2010Co-Authors: Richard E Scranton, Anthony H CincottaAbstract:Importance to the field: There is a large unmet need for new therapies to treat type 2 diabetes (T2DM) which reduce fasting and postprandial glucose without increasing insulin levels and which are not associated with weight gain or hypoglycemia. The quick-release formulation of Bromocriptine (Bromocriptine-QR; Cycloset™) represents such a therapy.Areas covered in the review: Bromocriptine-QR's proposed mechanism of action, unique formulation and clinical efficacy and safety will be discussed. A Medline search was conducted using the terms: Bromocriptine quick-release, circadian rhythms, treatment type 2 diabetes, insulin resistance, beta-cell dysfunction (years 1985 – 2009).What the reader will gain: The reader will gain an understanding of the importance of the brain as a target for the treatment of type 2 diabetes. In addition the safety, efficacy and indication for use of a first-in-class dopamine agonist as a treatment option for type 2 diabetes are discussed.Take home message: Bromocriptine-QR is ind...
